Print

ChemDiv, Inc. Receives Multiple Milestones in Major Drug Discovery Collaboration With Eli Lilly and Company (LLY)  
12/19/2012 7:03:07 AM

SAN DIEGO, CA--(Marketwire - December 19, 2012) - ChemDiv, Inc., a fully integrated drug discovery and development contract research organization with research facilities in San Diego, USA and Moscow, Russia, announced receipt of several milestones across three major therapeutic areas resulting from its collaboration with Eli Lilly. Financial details were not disclosed.

Alex Kiselyov, Ph.D., President of ChemDiv commented: "Using our integrated drug discovery platforms, a team of chemists and biologists at ChemDiv, Inc. identified multiple active series to supplement therapeutic programs at Eli Lilly. This is yet another step in our successful collaborative efforts with pharma and biotech partners to identify advanced preclinical drug candidates."

About ChemDiv

ChemDiv, Inc. is a Fully Integrated Target-to-Clinic Contract Research Organization (CRO) headquartered in San Diego, CA USA. The company features multiple research and development (R&D) subsidiaries in Russia, Ukraine and China as well as business and logistics operations around the world. It engages pharmaceutical and biotech partners by offering 'one stop' drug discovery and development services based on a project-, FTE- and risk sharing collaborative modes. ChemDiv has ongoing R&D collaborations in a number of functional areas and across multiple therapeutic platforms with Abbott Laboratories, Johnson & Johnson, Mitsubishi Tanabe, UCB as well as research contracts in programs of ChemRar Group in partnerships with Pfizer, Hoffman-La Roche and others. More info about ChemDiv is available at www.chemdiv.com.


Contact for media:
Alex Kiselyov
ChemDiv, Inc.
Email Contact
tel 858 794 4860


//-->